Nesfatin-1 Levels Predict Angiographic No-Reflow in Patients with ST-Segment Elevation Myocardial Infarction
Yazarlar (4)
Serkan Sivri
Kirsehir Ahi Evran University
Kirsehir Ahi Evran University
Prof. Dr. Erdoğan SÖKMEN Kırşehir Ahi Evran Üniversitesi, Türkiye
Mustafa Çelik Kırşehir Ahi Evran Üniversitesi, Türkiye
Kenan Güçlü Kirsehir Ahi Evran University
| Makale Türü | Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale) | ||
| Dergi Adı | Acta Cardiologica Sinica | ||
| Dergi ISSN | 1011-6842 Wos Dergi Scopus Dergi | ||
| Dergi Tarandığı Indeksler | SCI-Expanded | ||
| Makale Dili | İngilizce | Basım Tarihi | 07-2020 |
| Kabul Tarihi | 12-04-2026 | Yayınlanma Tarihi | – |
| Cilt / Sayı / Sayfa | 36 / 4 / 318–325 | DOI | 10.6515/ACS.202007_36(4).20200207A |
| Makale Linki | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355118/pdf/acs-36-318.pdf | ||
| Özet |
| Background Nesfatin-1 is a novel peptide possessing pleiotropic metabolic effects. No-reflow phenomenon (NR) is a poor prognostic indicator occurring in around 30% of all patients undergoing primary percutaneous coronary interventions (pPCI). Inflammation and complexity of coronary artery disease (CAD) play pivotal roles in the pathogenesis of NR. In this study, we investigated the relationship between admission serum nesfatin-1 level, NR and complexity of CAD assessed by SYNTAX-1 (SS-1) and SYNTAX-2 (SS-2) scores in patients with ST-segment elevation myocardial infarction (STEMI) undergoing pPCI. Methods A total of 174 STEMI patients who underwent pPCI were included in the study and divided into NR (n = 36) and normal flow (n = 138) groups. Serum nesfatin-1 was measured by enzyme-linked immunosorbent assay. Seventy-eight consecutive age-, gender- and co-morbidity-matched patients … |
| Anahtar Kelimeler |
| Acute myocardial infarction | Nesfatin-1 | No-reflow phenomenon | SYNTAX score |
BM Sürdürülebilir Kalkınma Amaçları
| Atıf Sayıları | |
| Google Scholar | 5 |
| Web of Science | 5 |